Page 8 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

2.5. Releasing resources and budget for your entire centre

 Based on experience with trastuzumab SC, using SC formulations could reduce
IV infusion chair times for patients by as much as 90%. 37,40-42
 Shorter chair times are expected to improve patient throughput, allowing

greater patient access and shortening waiting lists. 37,39
 Other perceived benefits of fixed-dose SC combination include:

01 02 03 04 05
Less Reduced Reduced More
resource costs Less drug costs for IV efficient
use for due to lost wastage 43 preparation use of
administration 43 staff times 43 storage
productivity 41 space 43

3. COMBINING THE ANTIBODIES YOU KNOW IN ONE FASTER

MODE OF ADMINISTRATION

Pertuzumab and trastuzumab are recombinant humanized IgG1κ monoclonal
antibodies, which target HER2, a transmembrane glycoprotein with intrinsic tyrosine
kinase activity. Pertuzumab and trastuzumab bind to distinct HER2 epitopes without

competing and have complementary mechanisms for disrupting HER2 signaling,
resulting in augmented anti-proliferative activity when given in combination. 35,36

The fixed-dose SC combination of trastuzumab and pertuzumab is a faster
treatment option for your patients and practice. 35,39

Faster administration with fixed-dose subcutaneous combination of
trastuzumab and pertuzumab vs IV PERJETA + trastuzumab* 35,39
®

Loading Dose
Fixed-dose SC
combination of trastuzumab
and pertuzumab ~8 minutes
IV PERJETA ® IV PERJETA ® : 60 minutes IV trastuzumab: 90 minutes
+ trastuzumab

Maintenance Dose
Fixed-dose SC
combination of trastuzumab ~5 minutes
and pertuzumab
IV PERJETA ® IV PERJETA ® : 30-60 minutes IV trastuzumab: 30-90 minutes
+ trastuzumab
0 20 40 60 80 100 120 140 160
0 20 40 60 80 100 120 140 160
administration time (minutes)

M-AE-00000086 8